- Home
- SNGX vs APM Comparison
SNGX vs APM Comparison
Compare SNGX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- APM
- Stock Information
- Founded
- SNGX 1987
- APM 2010
- Country
- SNGX United States
- APM United Kingdom
- Employees
- SNGX N/A
- APM N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- APM Health Care
- Exchange
- SNGX Nasdaq
- APM Nasdaq
- Market Cap
- SNGX 6.5M
- APM 6.1M
- IPO Year
- SNGX 1987
- APM 2018
- Fundamental
- Price
- SNGX $1.89
- APM $0.92
- Analyst Decision
- SNGX
- APM
- Analyst Count
- SNGX 0
- APM 0
- Target Price
- SNGX N/A
- APM N/A
- AVG Volume (30 Days)
- SNGX 18.7K
- APM 28.8K
- Earning Date
- SNGX 05-09-2025
- APM 06-10-2025
- Dividend Yield
- SNGX N/A
- APM N/A
- EPS Growth
- SNGX N/A
- APM N/A
- EPS
- SNGX N/A
- APM N/A
- Revenue
- SNGX $2,342.00
- APM N/A
- Revenue This Year
- SNGX N/A
- APM N/A
- Revenue Next Year
- SNGX N/A
- APM N/A
- P/E Ratio
- SNGX N/A
- APM N/A
- Revenue Growth
- SNGX N/A
- APM N/A
- 52 Week Low
- SNGX $1.68
- APM $0.46
- 52 Week High
- SNGX $14.83
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- SNGX 45.39
- APM 51.22
- Support Level
- SNGX $1.85
- APM $0.83
- Resistance Level
- SNGX $1.95
- APM $1.00
- Average True Range (ATR)
- SNGX 0.09
- APM 0.08
- MACD
- SNGX 0.01
- APM -0.00
- Stochastic Oscillator
- SNGX 42.11
- APM 44.24
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.